News | ECG | September 06, 2023

Vektor Medical Unveils Enhanced vMap Technology for Accurate, Non-invasive Mapping of Cardiac Arrhythmias

Updated AI-based software is designed to improve cardiac ablation outcomes and procedural efficiencies 

Updated AI-based software is designed to improve cardiac ablation outcomes and procedural efficiencies

With advanced visualization and automation features, vMap empowers physicians to accurately identify the source location of cardiac arrhythmias. (Graphic: Business Wire) 


September 6, 2023 — Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ECG data, announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap. Designed to improve ablation outcomes and procedural efficiencies, the newly updated vMap software integrates additional automation and advanced visualization features. 

vMap is the only FDA-cleared, AI-based non-invasive solution that unlocks the data contained in a standard 12-lead ECG, enabling physicians to rapidly and accurately locate arrhythmia source locations. The software upgrades are designed to improve the accuracy, visualization, and efficiency of arrhythmia analysis and interpretation. The updates include: 

Beat Assist: Software recommends and auto-selects arrhythmic beats of interest that may indicate the source location of an arrhythmia. This new functionality reduces uncertainty and increases confidence when identifying arrhythmic beats, speeding up procedure planning process. 

Upgraded Heart Model: vMap’s new model provides a highly realistic and more detailed representation of the heart. It improves visualization and understanding of spatial distribution of the target lesion sites, increasing analysis accuracy and translation. 

Automated ECG Baseline Correction: The revolutionary signal conditioning removes baseline noise from input ECG signals, improving accuracy and ultimately providing higher-quality ECG signals for analysis. 

“The vMap software upgrades and enhanced visualization capabilities have made a significant impact on my ability to see the arrhythmia source location and plan the EP procedure,” stated Dr. Greg Feld, Director of Electrophysiology at UC San Diego Health. “The level of detail and clarity solidify vMap as a cutting-edge solution in arrhythmia care and will empower EPs to navigate the heart with more accuracy and confidence." 

In addition, the upgrades include a series of workflow enhancements to simplify analysis, aid with pattern recognition and abnormality identification and reduce mapping time. These updates highlight Vektor Medical’s commitment to continuous innovation to transform arrhythmia care. 

For more information: www.vektormedical.com


Related Content

News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
News | FDA

May 8, 2024 — 4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally ...

Home May 08, 2024
Home
News | FDA

May 7, 2024 — RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology ...

Home May 07, 2024
Home
News | FDA

April 25, 2024 — Provisio Medical announced FDA 510(k) clearance of the Provisio SLT IVUS System. Sonic Lumen Tomography ...

Home April 25, 2024
Home
News | FDA

April 24, 2024 — Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food ...

Home April 24, 2024
Home
News | FDA

April 22, 2024 — At the annual American College of Cardiology conference (ACC.24) in Atlanta last week, RCE Technologies ...

Home April 22, 2024
Home
News | FDA

April 18, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently ...

Home April 18, 2024
Home
News | FDA

April 15, 2024 — The U.S. Food and Drug Administration (FDA) announced Abbott/Thoratec Corp. is recalling HeartMate II ...

Home April 15, 2024
Home
Subscribe Now